IOncology

The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting took place from May 30 to June 3 in Chicago. At this high-profile event, Professor Kun Wang from Guangdong Provincial People’s Hospital presented the much-anticipated results of the neoCARHP study (Abstract LBA500) during an oral session. The study, which focuses on early-stage HER2-positive breast cancer, offers an innovative head-to-head comparison between a carboplatin-free THP regimen and the traditional carboplatin-containing TCbHP regimen. The findings revealed that the THP regimen was non-inferior to TCbHP in terms of pathological complete response (pCR), with a significantly better toxicity profile. This important discovery not only provides a new therapeutic option for patients with HER2-positive breast cancer but also reflects a patient-centered approach to treatment—marking a shift toward more precise and individualized care. Following the presentation, Oncology Frontier interviewed Professor Wang to discuss the study’s background, significance, and what the future holds for HER2-positive breast cancer treatment.

Editor’s Note: The 2025 ASCO annual meeting was held from May 30 to June 3 in Chicago, USA. At this annual meeting, a number of research results carried out by…

Sacituzumab Tirumotecan (sac-TMT) is a novel TROP2-targeted ADC independently developed in China. Over the past two years, its clinical findings have been frequently presented at major international conferences and published in top-tier journals. At the 2025 ASCO Annual Meeting, Professor Yongmei Yin from Jiangsu Provincial People’s Hospital delivered a Rapid Oral Abstract presentation on the phase II OptiTROP-Breast05 study, which evaluated sac-TMT as a first-line therapy for advanced triple-negative breast cancer (TNBC). The results demonstrated impressive efficacy and a favorable safety profile. Oncology Frontier invited Professor Yongmei Yin at the conference to discuss the study's key outcomes and how sac-TMT, as a leading TROP2 ADC, is poised to make a lasting impact on breast cancer treatment in China and globally.

In 2025, Dr. Husam Abu Jazar and colleagues at King Hussein Cancer Center published two impactful studies that could shape transplant care moving forward. The first study analyzed outcomes from…

The therapeutic landscape in oncology is undergoing a profound shift with the rise of genome engineering technologies such as CRISPR/Cas9, base editing, and prime editing. These tools are enabling the…

Introduction Gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma are among the most aggressive malignancies, particularly in their advanced stages. The CheckMate 649 trial previously established nivolumab plus chemotherapy as a superior first-line treatment compared to chemotherapy alone. With five years of follow-up, this latest analysis provides crucial insights into long-term survival, disease progression, and safety outcomes in Chinese patients. Given that nivolumab plus chemotherapy has been approved in over 50 countries as a first-line treatment, this updated evaluation assesses whether its benefits remain sustained over time in this population.

Although published in 2023, the MAINTAIN trial remains a key reference in the evolving management of HR+/HER2− metastatic breast cancer following progression on CDK4/6 inhibitors.In this randomized, placebo-controlled phase II…

The 2024 European Society for Medical Oncology (ESMO) Annual Meeting was held in Barcelona, Spain. A Phase III randomized controlled trial (SYLT-021), led by Dr. Rongbo Lin’s team from the Department of Gastrointestinal Oncology, Fujian Cancer Hospital, was selected as one of six Proffered Paper oral presentations in the palliative care session. This study compared hydromorphone intravenous patient-controlled analgesia (IPCA) with oral morphine for severe cancer pain management.